



(51) International Patent Classification:

A61K 31/475 (2006.01) A61P 35/00 (2006.01)
A61K 31/337 (2006.01)

(21) International Application Number:

PCT/IB2016/001132

(22) International Filing Date:

21 July 2016 (21.07.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/195,243 21 July 2015 (21.07.2015) US

(71) Applicant: KINEX THERAPEUTICS (HK) LIMITED
[CN/CN]; 11/F Axa Center, Gloucester Road, 151, Hong
Kong (CN).

(72) Inventors: KWAN, Min-fun, Rudolf; 9 Friar Tuck Circle,
Summit, NJ 07901 (US). KRAMER, E., Douglas; 71
Kensington Road, Stamford, CT 06905 (US). FET-
TERLY, Geralk, J.; 44 Huntwood Court, Getzville, NY
14068 (US). HUNG, Cheung-tak; 88 Campbells Road,
Pine Hill, Dunedin, 9010 (NZ). JACKSON, Christopher
Glyn Charles, Alexander; 83 Norfolk Street, St Clair, Du-
nedin, 9012 (NZ). GLUE, Paul, William; Department Of
Psychological Medicine, University Of Otago, Po Box 56,
Dunedin, 9054 (NZ).

(74) Agent: CHINA PATENT AGENT (H.K.) LTD.; 22/F.,
Great Eagle Center, 23 Harbour Road, Wanchai, Hong
Kong (CN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

2 March 2017

(54) Title: THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED PACLITAXEL AND A P-GP INHIBITOR FOR THE TREATMENT OF CANCER

(57) Abstract: The application pertains to pharmaceutical combinations of orally administered paclitaxel and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of cancer in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered paclitaxel (e.g., Taxol® or paclitaxel formulated with Cremophor®) therapy in a subject suffering from cancer.



INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB2016/001132

A. CLASSIFICATION OF SUBJECT MATTER

A61K 31/475(2006.01)i; A61K 31/337(2006.01)i; A61P 35/00(2006.01)i

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, EPODOC, CPRS(CN), CNKI, CTMPD(CN), CHEMICAL PHARMACEUTICAL ABSTRACT(CPA), STN: structure search of compound A, paclitaxel, cancer, tumour, tumor, hematologic toxicity, neurotoxicity, hypersensitivity

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Sebastian C.Koehler et al. "HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2)" <i>Journal of Medicinal Chemistry</i> , Vol. 58, 09 April 2015 (2015-04-09), pages 3910-3921, especially the abstract	1-66, 73-75
Y	Sebastian C.et al. "HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2)" <i>Journal of Medicinal Chemistry</i> , Vol. 58, 09 April 2015 (2015-04-09), pages 3910-3921, especially the abstract	67-72, 76-78
Y	Jin-Oh Kwak et al. "Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel" <i>European Journal of Pharmacology</i> , Vol. 627, 31 December 2010 (2010-12-31), pages 92-98, especially the abstract	67-72, 76-78

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

05 January 2017

Date of mailing of the international search report

17 January 2017

Name and mailing address of the ISA/CN

STATE INTELLECTUAL PROPERTY OFFICE OF THE
P.R.CHINA
6, Xitucheng Rd., Jimen Bridge, Haidian District, Beijing
100088
China

Authorized officer

FAN,Chanjuan

Facsimile No. (86-10)62019451

Telephone No. (86-10)62411209

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB2016/001132

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **67-69**
because they relate to subject matter not required to be searched by this Authority, namely:

[1] These claims relate to methods for treating diseases (PCT R39.1(iv)), but the search has been carried out and based on the use of paclitaxel and compound A in manufacture of medicaments for treating corresponding diseases.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).